Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, talks on the management of Bing-Neel syndrome (BNS), emphasizing the importance of individualizing treatment in these patients. There is currently no prospective data evaluating therapies in BNS. Therefore, clinicians make treatment decisions based on data from small retrospective studies. Treatment options currently include methotrexate-cytarabine-based therapies as well as less intensive options and BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.